Research · 10 min read
Your microbiome and hormone therapy: what the new Nature Medicine research means (and doesn't) for you.
Hormone therapy can ease bothersome hot flashes and night sweats, but not everyone improves at the same pace, or in the same ways. A study published November 3, 2026, in Nature Medicine, and summarized in a November 13 research briefing, offers a careful look at one possible reason: the communities of microbes that live in the gut and the vagina.
The findings are interesting. They are also early. This was one population, one oral regimen, and a six-month study without a placebo group. It is not a test your clinician can order today, and it does not change the basic work of menopause care: a full history, a conversation about benefits and risks, and follow-up if treatment needs adjusting. This article does not advise you to start, stop, or change any medicine, and it does not recommend a microbiome test; those decisions belong with you and a licensed clinician.
The estrobolome and the vaginal microbiome, in plain language
"Microbiome" just means the community of microbes that live in a particular place in the body. Two communities show up in this research.
In the vagina, estrogen helps the lining store glycogen, which supports Lactobacillus species that help keep the environment acidic. When estrogen falls during the menopause transition, that Lactobacillus-dominant pattern often weakens. The Nature Medicine paper notes that this shift is one contributor to genitourinary syndrome of menopause—vaginal dryness, irritation, and related urinary symptoms—and to recurrent urinary tract infections.
In the gut, some bacteria make enzymes called β-glucuronidases that can convert inactive estrogen conjugates back into active estrogen, which can then be reabsorbed. That collection of estrogen-recycling activity is often called the estrobolome. The Nature Medicine research briefing cites laboratory work on this pathway. It is a useful frame for reading the new study. It is not, by itself, proof that a particular gut microbe will make hormone therapy work better or worse for you.
What the study actually found
Researchers enrolled 356 symptomatic perimenopausal women, aged 40 to 55 years (mean 47.48 ± 2.92), at 14 centers in China. All received a standardized oral estradiol/dydrogesterone regimen for six months as part of routine care: estradiol 1 mg daily on days 1–14 of each 28-day cycle, then estradiol 1 mg plus dydrogesterone 10 mg daily on days 15–28 (Femoston 1/10). The authors note that this product is not commercially available in the United States or the United Kingdom. Naming a product here does not mean Kindr Health prescribes it.
This was not a randomized, placebo-controlled trial. The investigators did not assign or change treatment; they observed women already receiving this regimen. Of 434 women screened, 356 were enrolled. Visits were scheduled at baseline and at weeks 4, 12, and 24; 295 participants (82.9%) completed 24 weeks. Symptoms were scored with a modified Kupperman Index (mKI), a 13-item menopausal symptom scale, along with measures of sleep, mood, and sexual function.
After 24 weeks, symptoms had improved for most participants. The median mKI fell 63.0%, and 96.9% of participants had a sustained mKI reduction at week 24. Sexual function, measured by the Female Sexual Function Index (FSFI), rose a median of 13.6%, with improvement in 60.3%. Because there was no placebo group, some of that change could reflect time, a placebo effect, or regression to the mean—limits the authors themselves emphasize.
The microbial changes were site-specific. The vaginocervical community changed the most, with related shifts in the urinary microbiome, more modest changes in the mouth, and little change in the gut. During hormone therapy, vaginocervical Lactobacillus crispatus increased and Gardnerella vaginalis decreased. Compared with reference samples from healthy reproductive-age women (ages 35–40) and postmenopausal women in a public Chinese dataset, the participants' vaginal microbiome at baseline sat in between. By week 24, it had shifted toward the reproductive-age reference: mean relative abundance of L. crispatus rose from 15.1% at baseline to 26.0% (the reproductive-age reference was 27.6%; the postmenopausal reference was 3.3%). That shift was already visible at week 4 and then stabilized.
Starting microbial patterns were also linked to how people fared. Women whose vaginal community was dominated by G. vaginalis at baseline showed the most movement toward communities usually considered healthier. Those with a diversified vaginal community improved the least. Higher baseline vaginocervical L. crispatus was linked to greater L. crispatus colonization later and to better FSFI improvement.
The gut community changed little during treatment, but its starting type was linked to outcomes. At baseline, 80.6% of participants had a Phocaeicola vulgatus-dominated community and 19.4% had a Prevotella copri-dominated community; only 5.6% switched type by week 24. The P. vulgatus group showed greater hormonal responsiveness and better clinical outcomes. They were more likely to be classified as hormonal responders (72.1% versus 52.2%; odds ratio 2.37, 95% CI 1.22–4.60) and more likely to reach a rapid clinical response, defined as an mKI of 7 or less at week 4 (38.7% versus 23.5%; odds ratio 2.05, 95% CI 1.05–4.28). The authors suggest this may reflect differences in estrogen recycling through the estrobolome; that is a hypothesis, not something this study proved.
A model that combined baseline symptoms and gut microbial features predicted rapid symptom improvement better than clinical features alone (area under the curve 0.793 versus 0.701 on a held-out test set). The research briefing calls this a "blueprint for precision menopausal care." That is a research goal, not a clinic-ready test.
What this research does not mean
Several limits should shape how you read the headlines.
- One population. Every participant was a perimenopausal woman receiving care at centers in China, aged 40 to 55, with an intact uterus and ovaries and an mKI of at least 14. Results may not apply to postmenopausal women, to other ages, or to people in other countries.
- One oral regimen. Everyone took the same estradiol/dydrogesterone tablets. The findings may not apply to patches, gels, other pills, or local vaginal estrogen. The authors say generalizability to other estrogen-progestogen products needs more study.
- No placebo group, and not a clinical test. The before-and-after design, which the authors say they used primarily for ethical reasons, cannot fully separate the effect of hormone therapy from time, placebo effects, or regression to the mean. The design also limits causal claims. There is no validated microbiome test that should guide whether to start hormone therapy, or which product to choose, based on this paper.
The study also reported mixed laboratory changes, including some procoagulant shifts, and the authors wrote that individualized risk assessment and monitoring remain essential.
Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. People who have a uterus and use systemic estrogen typically still need a progestogen.
In November 2025, FDA asked manufacturers of menopausal hormone therapies to remove language about cardiovascular diseases, breast cancer, and probable dementia from the boxed warning. FDA's public list of products with updated prescribing information—content current as of October 30, 2026—names nine products. The list page itself does not spell out what changed on each label. We reviewed the nine FDA-approved labels linked from that list, as posted on November 14, 2026; some versions of these labels published elsewhere, including on DailyMed, may not yet reflect every update. On the systemic estrogen-alone products on the list (Divigel, Cenestin, Enjuvia, Minivelle, Vivelle, and Vivelle-Dot), those three topics are no longer in the boxed warning; a boxed warning about endometrial cancer with unopposed estrogen remains. On Bijuva, a systemic estrogen-plus-progestogen product, the boxed warning was removed. The current Prometrium and Estring labels we read do not include a boxed warning. "Removed from the boxed warning" is not "no risks." For systemic products, FDA asked that cardiovascular disease and breast cancer warnings remain in the labeling. See our boxed-warning explainer for what those changes did and didn't do. Hormone therapy also remains contraindicated in specific situations, which we reviewed separately.
For people seeking treatment of menopausal vasomotor symptoms—hot flashes and night sweats—the American College of Physicians (ACP) recommends estrogen with a progestogen in people who have a uterus, or estrogen alone in people who do not, as first-line pharmacologic treatment. That is not an automatic yes for every person, and a microbiome result should not override a clinician's assessment of benefits, harms, and contraindications.
What is useful to take away now
Response to hormone therapy varies. In this study, most participants improved, but the pace and the pattern were not uniform—especially for sexual function, and especially when researchers looked at starting gut and vaginal community types. If you start treatment and you are not getting the relief you hoped for, that is useful information for a follow-up visit. It is not a reason to order a gut or vaginal microbiome test on the basis of this paper.
Local vaginal estrogen is a different tool for genitourinary symptoms. The Nature Medicine study used oral hormone therapy and watched the vaginal microbiome change. That is not the same as treating vaginal dryness or irritation with a local vaginal product. FDA has approved menopausal hormone therapies for moderate to severe symptoms of vulvar and vaginal atrophy (also called genitourinary syndrome of menopause). Estring, the topical vaginal estrogen on FDA's updated-label list, is indicated for moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Some systemic product labels also say that when the only goal is to treat those local symptoms, topical vaginal products should be considered first. Naming a product does not mean Kindr Health prescribes it, or that it is right for you.
Follow-up visits, and dose or route changes, still matter. People in this study responded differently to the same oral regimen. If symptoms persist, or side effects appear, a clinician may consider a different dose or a different route. ACP asks clinicians to use informed decision-making and to discuss benefits, harms, contraindications, other conditions, values and preferences, cost, and access. FDA's labeling request for systemic products also asked companies to add consideration of starting hormone therapy for moderate to severe hot flashes in women younger than 60 or less than 10 years since menopause—guidance about starting, not a stop rule, which we discussed in a recent post. Those are clinical judgments, not something this article can make for you.
Where Kindr fits
At Kindr Health, menopause and midlife care is clinician-led. Conversations about hormone therapy are individualized: your symptoms, your health history, and your goals. Kindr Health is a telehealth platform that connects patients with licensed clinicians, who can talk through whether hormone therapy is appropriate for you, what nonhormonal options may be available, and whether a local vaginal estrogen is relevant for genitourinary symptoms. This research may eventually help explain why responses differ. It does not replace a careful visit, and it is not a test you need before care. Kindr Care patient intake is open now.
This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.
Sources
- Chen C, Hao L, Xie W, Tang R, et al. Heterogeneity of microbiome responses to menopausal hormone therapy among perimenopausal women. *Nat Med*. Published November 3, 2026. doi:10.1038/s41591-026-04737-4. Chinese Clinical Trial Registry ID: ChiCTR2100049768 — www.nature.com/articles/s41591-026-04737-4
- Chen C, Hao L. Gut and urogenital microbiomes influence menopausal hormone therapy outcomes. *Nat Med*. Research Briefing. Published November 13, 2026. doi:10.1038/s41591-026-04789-6 — www.nature.com/articles/s41591-026-04789-6
- American College of Physicians, "ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms" (October 5, 2026) — www.acponline.org/acp-newsroom/acp-recommends-hormonal-therapy-as-a-first-line-treatment-for-menopausal-vasomotor-symptoms
- FDA, Menopausal Hormone Therapies with Updated Prescribing Information (content current as of October 30, 2026) — www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
- FDA, Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies (November 10, 2025; content current as of February 12, 2026) — www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
- Current FDA labels for the nine products on the updated-prescribing-information list, retrieved November 14, 2026 — www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information
- Kindr journal: "Removed from the boxed warning": what changed—and what it means for you — kindr.health/journal/boxed-warning-removed-what-changed-brain-estrogen
- Kindr journal: Who shouldn't take hormone therapy? Contraindications, gray areas, and your non-hormonal options — kindr.health/journal/who-shouldnt-take-hormone-therapy
- Kindr journal: Is there an age limit on hormone therapy? Timing, the 10-year window, and HT after 60 and 65 — kindr.health/journal/is-there-an-age-limit-on-hormone-therapy
Medically reviewed by Kindr Health Clinical Team
Last updated: November 14, 2026
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Is HRT safe?Journal
- When to start HRTJournal
- Menopause HRT serviceMedication
- Complete menopause guideJournal
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.